Avalo Therapeutics Acquires Aevi Genomic Medicine

Avalo Therapeutics is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan diseases, as well as neurological conditions. Avalo Therapeutics, Inc. is building a robust pipeline of innovative therapies. Avalo Therapeutics's pediatric rare disease pipeline is led by CERC-801, CERC-802, and CERC-803 (“CERC-800 programs”), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation. The FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation (“ODD”) to all three CERC-800 compounds, thus qualifying the Company to receive a Priority Review Voucher (“PRV”) upon approval of a new drug application (“NDA”). Avalo Therapeutics was founded in 2011 and is based in Rockville, Maryland.